|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.6271 - 0.6557|
|52 Week Range||0.4350 - 1.3700|
|Beta (3Y Monthly)||2.61|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (TBPMF), is pleased to announce that Mr. Derek Theriault has been hired as National Sales Director and Michael Olders has been hired as Director Operations and Logistics. Derek Theriault, National Sales Director – has 20 years’ experience within the pharmaceutical industry and has held various sales and leadership roles during this time.
TORONTO , Jan. 10, 2019 /CNW/ - With the recent legalization of recreational cannabis in Canada , a major gap has been revealed, and that is a lack of scientific research on the health effects of its use – both on the recreational and medical side. The Lung Association – Ontario and Tetra Bio-Pharma are excited to be partnering to fill that gap by funding a research program that will investigate various health impacts of cannabis use. The goal of this program will be to better support patients and healthcare providers with evidence-based information.
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) today announced that its Phase 1 clinical trial in healthy volunteers using vaporized PPP001 has been successfully concluded. Tetra Bio-Pharma also completed a first series of analyses of the cannabis vapor generated by the Mighty Medic vaporizer manufactured by Storz & Bickel, thus providing a deeper understanding of the process of administering cannabinoids to patients. “We are thrilled with the results of this trial which was completed both on time and on budget,” stated Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma.
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (TBPMF) a leader in cannabinoid-based drug discovery and development confirms its non-exclusive supply agreement for GMP-Grade THC with U.S.-based Rhodes Technologies Inc. The supply will be used for several drug development activities including Tetra’s cannabinoid-derived products PPP002, PPP003, and PPP004, as well as for discovery phase projects. This is additional to having a supply agreement with True North Cannabis Inc. for CBD from hemp which was necessary to meeting the demand associated with the Genacol Corporation transaction.
Tetra Bio-Pharma Inc (“Tetra” or the “Company”) (TSX VENTURE: TBP) (TBPMF), a leader in cannabinoid-based drug discovery and development has announced that it is in process of filing a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that allows for patent protection. “This patent application, if granted, would provide Tetra with full protection of its PPP001 prescription drug product. This will put PPP001 in the same category as any other innovative prescription drug,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma.
Tetra Bio-Pharma Inc (“Tetra” or “TBP”), (TSX VENTURE: TBP) (TBPMF), – announced that it held its first National Advisory Board meeting in Toronto, on November 30, 2018 as a platform to validate their drug development and commercial programs. “I am confident that this will be the first of many transparent and collaborative exchanges that Tetra organizes with physicians as we seek to bring cannabinoid-derived medicines into our healthcare system,” said Steeve Neron, Senior Vice-President, Marketing and Medical Affairs. Tetra Bio-Pharma (TBP.V) (TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.
Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (TBPMF), announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink, the first hemp energy drink in Canada, to meet growing demand in Canada and to make Hemp Energy Drink available across all regions of the country. Canadian consumers appreciate the qualities of Hemp Energy Drink (www.hempenergydrink.ca) that contains fewer calories and more natural ingredients than other energy drinks, and the product will be available soon everywhere in Canada in three flavors: classic, mango and raspberry.
Tetra Bio-Pharma Inc (“Tetra” or “TBP”), (TSX VENTURE: TBP) (TBPMF), has closed a private placement of units (the “Private Placement”) with its strategic partner Aphria Inc. (“Aphria”) (APHA.TO) (APHA). Under the Private Placement, Tetra issued to Aphria (6,900,000) units (the “Units”), with each unit being comprised of one Class A common share of Tetra (a “Common Share”) and one Common Share purchase warrant (a “Warrant”), at a price of $1.03 per unit, which is the closing price of the Common Shares on the TSX Venture Exchange on November 28, 2018, for gross proceeds of $7,107,000.
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (TBPMF), and Altus Formulation Inc. (“Altus”) today announced the signing of a non-binding term sheet ("Term Sheet") to create a joint-venture to formulate, develop and deliver cannabinoid derived therapeutics for a number of indications. Altus has three distinct drug delivery technologies that will provide Tetra with significant strategic advantages over the competition.
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (TBPMF), is pleased to update the market that Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma will be travelling to Washington, D.C. today for individual meetings with six high-ranking U.S. Senators. The meetings, scheduled for November 26th and 27th, have a mutually beneficial purpose, namely expanding Tetra’s existing work with Health Canada and the FDA in the United States as well as briefing the Senators on Tetra Bio-Pharma’s unique approach which combines the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
ORLEANS, Ontario, Nov. 20, 2018 -- Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Quantum Pharma Inc. (“Quantum”) today announced the signing.
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) (TSX VENTURE: TBP) (TBPMF) and Panag Pharma Inc. (“Panag”) today announced the submission of a clinical research application to the Veterinary Drugs Directorate at Health Canada. This first of a kind veterinary study will examine the use of a cannabinoid-based drug to treat ocular pain and inflammation in canines.
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (TBPMF), is pleased to announce the promotion of Steeve Néron as Senior Vice President, Marketing and Medical Affairs.
Tetra Bio-Pharma Inc., ("Tetra" or the "Company"), a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (TBPMF), today announced it has entered into a non-binding proposal (the "Proposal") with the shareholders (the "Vendors") of Panag Pharma Inc. ("Panag") for the acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag (the "Proposed Transaction"). Panag is a Canadian-based life sciences company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Panag has developed innovative and patented formulations for the treatment of ocular diseases and other pain conditions such as general neuropathic pain.
Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE: TBP) (TBPMF), today announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii. The Hemp Energy Drink provides consumers with a product that contains fewer calories and more natural ingredients than existing energy drinks thus providing a welcome alternative to existing products in what is considered to be an extremely lucrative market.
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) today announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001. This study aims to determine the Pharmacokinetic and safety profile of PPP001 delivered as an inhaled vapour using the Mighty Medic (see previous July 16, 2018 News Release), thus providing patients with an alternative to the smoked version of PPP001 and allowing Tetra to develop PPP001 for healthier patients suffering from uncontrolled pain. It is anticipated that this phase 1 data, combined with Tetra’s characterization of the composition of vapor, will provide the necessary evidence to advance the development of vaporized PPP001 into more chronic and non-life-threatening diseases, such as fibromyalgia.
ORLEANS, ON , Oct. 16, 2018 /CNW/ - October 17 th, 2018 will be remembered as one of the most significant dates in Canadian history, in our lifetime. While there will continue to be arguments on both sides of the debate, the Government of Canada has legislated that adults will have access to cannabis for recreational use, subject to a set of guidelines that will vary from province to province. Tetra Bio-Pharma (TSX VENTURE: TBP) (TBPMF), is a Canadian company that is a global leader in the discovery and development of cannabis and cannabinoid-based pharmaceuticals and is the only company in North America to work with both Health Canada and the U.S. Food and Drug Administration on clinical programs to produce the rigorous scientific evidence required by these regulators as well as by medical professionals and insurance companies.
Media Advisory - Dr. Chamberland, Expert Spokesperson available to discuss legalization of recreational cannabis